75 related articles for article (PubMed ID: 35989458)
1. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
2. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
[TBL] [Abstract][Full Text] [Related]
3. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
4. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
5. [Severe consciousness disturbance after cord blood transplantation for relapsed T lymphoblastic lymphoma].
Nakamura N; Mizumoto C; Sugimoto A; Fujimoto M; Ayaki T; Takaori-Kondo A
Rinsho Ketsueki; 2024; 65(1):47-51. PubMed ID: 38311389
[TBL] [Abstract][Full Text] [Related]
6. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
7. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
8. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
Si Lim SJ; Ford JB; Hermiston ML
Blood; 2023 Jun; 141(25):3019-3030. PubMed ID: 37018730
[TBL] [Abstract][Full Text] [Related]
9. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
10. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab and Nelarabine Treatment as Salvage Therapy for T-Lymphoblastic Lymphoma: A Case Report.
Castellanos G; Pardo L; López A; Cornago J; López JL; de Las Heras A; Díaz FJ; Martínez de Bourio M; Castillo E; Llamas P; Solán L
Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540125
[TBL] [Abstract][Full Text] [Related]
13. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Paolino J; Dimitrov B; Apsel Winger B; Sandoval-Perez A; Rangarajan AV; Ocasio-Martinez N; Tsai HK; Li Y; Robichaud AL; Khalid D; Hatton C; Gillani R; Polonen P; Dilig A; Gotti G; Kavanagh J; Adhav AA; Gow S; Tsai J; Li Y; Ebert BL; Van Allen EM; Bledsoe J; Kim AS; Tasian SK; Cooper SL; Cooper TM; Hijiya N; Sulis ML; Shukla NN; Magee JA; Mullighan CG; Burke MJ; Luskin MR; Mar BG; Jacobson MP; Harris MH; Stegmaier K; Place AE; Pikman Y
Clin Cancer Res; 2023 Nov; 29(22):4613-4626. PubMed ID: 37725576
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
Shi H; Yang F; Cao M; Xu T; Zheng P; Guo Y; Su G; Feng S; Li R; Liu R; Liu H; Ma L; Ke X; Hu K
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662205
[TBL] [Abstract][Full Text] [Related]
15. [Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)].
Saultier P; Simonin M; Beaumais TA; Rialland F; Alby-Laurent F; Lubnau M; Desplantes C; Jacqz-Aigrain E; Rohrlich P; Reguerre Y; Rabian F; Sirvent N; Plat GW; Petit A
Bull Cancer; 2022 Nov; 109(11):1132-1143. PubMed ID: 35863954
[TBL] [Abstract][Full Text] [Related]
16. T-cell lymphoblastic leukemia/lymphoma: relapse 16 years after first remission.
Elreda L; Sandhu M; Sun X; Bekele W; Cohen AJ; Shah M
Case Rep Hematol; 2014; 2014():359158. PubMed ID: 24822133
[TBL] [Abstract][Full Text] [Related]
17. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
Leong S; Inglott S; Papaleonidopoulou F; Orfinada K; Ancliff P; Bartram J; Carpenter B; Fielding AK; Ghorashian S; Grandage V; Gupta R; Hough R; Khwaja A; Pavasovic V; Rao A; Samarasinghe S; Vora A; Mansour MR; O'Connor D
Blood Adv; 2020 Oct; 4(19):4665-4668. PubMed ID: 33002130
[No Abstract] [Full Text] [Related]
18. [The consensus of the diagnosis and treatment of adult T-cell lymphoblastic lymphoma in China (2023)].
; ;
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):353-358. PubMed ID: 37550183
[No Abstract] [Full Text] [Related]
19. Etoposide-induced SENP8 confers a feed-back drug resistance on acute lymphoblastic leukemia cells.
Sun S; Cheng Y; Hou W; Yan Y; Meng T; Li H; Xiao N
Biochem Biophys Rep; 2024 Mar; 37():101650. PubMed ID: 38314144
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]